Five New EU Filings Leave Starting Blocks at EMA
Fast-Track Rejection For Amivantamab And Voxelotor
Executive Summary
There is one orphan drug among the five new marketing authorization applications that the European Medicines Agency has under review. All five drugs will be reviewed under standard review timelines.